Galaxa Pharma a/s: Financial statements 2024
CVR: 41183144
Source: annual report 2024, Danish Business Authority
01/10/2023 – 30/09/2024
Galaxa Pharma a/s (CVR 41183144) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -898,059 and a net result of DKK -819,815 compared with DKK -1,742,863 the year before. Equity in the 2024 report amounted to DKK 251,706. The solvency ratio was 15.7%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -898,059
- Profit/Loss
- DKK -819,815
- Equity
- DKK 251,706
- Total Assets
- DKK 1,598,353
- Employees
- 1
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -898K | -820K | 252K | 1 |
| 2023 | - | -2M | -1.7M | 572K | 1 |
| 2022 | - | -846K | -2M | 814K | 2 |
| 2021 | 666K | -6K | -134K | 360K | 1 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Galaxa Pharma a/s has published its annual report for 2023. Gross profit came to DKK -1,971,399, and the net result was DKK -1,742,863.
As of April 9, 2024, Ib Madsen has joined the board of directors of Galaxa Pharma a/s.
As of April 9, 2024, Flemming Heegaard has joined the board of directors of Galaxa Pharma a/s.
As of April 9, 2024, Jesper Herold Halle has joined the board of directors of Galaxa Pharma a/s.
As of April 9, 2024, Jørgen Flemming Ladefoged has left the board of directors of Galaxa Pharma a/s.
About Galaxa Pharma a/s
Galaxa Pharma a/s is a Danish company of the type Aktieselskab based in København Ø, founded in 2020. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named CanNordic A/S. The management consists of Lone Henriksen. The board consists of Gitte Henriksen, Jens Jørgen Hagelskjær and Lone Henriksen. The company is owned by CS MEDICA a/s. The company has 1 employee (2023). In 2025, the company reported a gross profit of DKK -398,874 and a net result of DKK -461,281 compared with DKK -819,815 the year before. Equity in the 2025 report amounted to DKK -209,574.